Application No. 09/843,161
Amendment dated October 14, 2005
Page 2

Amendments to the Claims:

The following claims will replace all prior versions of the claims in this application (in the unlikely event that no claims follow herein, the previously pending claims will remain):

1-60. (Cancelled).

61. 1. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

$$Z = \begin{bmatrix} A''_n \\ B''_m \end{bmatrix} X'$$

in a physiologically acceptable carrier;

wherein Z is

n, m, q and r independently represent integers from zero to 4 provided that n + m < 4 and q + r < 4; p and s independently represent integers from zero to 5 provided that p + s < 5; a and b represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R- or S- configuration;

Application No. 09/843,16. Amendment dated October 14, 2005 Page 3

R and R' each independently represent a hydrogen atom; linear or branched C1-C20 alkyl; linear or branched C2-C20 alkenyl; -CO2Z'; -CO2R'"; -NH2; -NHR"; -NR2"; -OH; -OR"; -CONR2""; halogen atom; optionally substituted linear or branched C₁-C₂₀ alkyl; optionally substituted linear or branched C2-C20 alkenyl;

R" independently represents a hydrogen atom; linear or branched C₁-C₂₀ alkyl; linear or branched C2-C20 alkenyl; -CO2Z'; -CO2R'"; -NH2; -NHR'"; -NR2"'; -OH; -OR"'; halogen atom; optionally substituted linear or branched C_I-C₂₀ alkyl; optionally substituted linear or branched C2-C20 alkenyl;

R" independently represents a linear or branched C_I-C₂₀ alkyl; or linear or branched C₂-C₂₀ alkenyl;

R"" independently represents a hydrogen atom; optionally substituted C_I-C₂₀ alkyl; or optionally substituted C₁-C₂₀ alkoxy;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, A' and A" each independently represent a hydrogen atom; C₁-C₂₀ acylamino; C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl;C₁-C₂₀ alkoxycarbonyl; C₁-C₂₀ alkoxy; C₁-C₂₀ alkylamino; C₁-C₂₀ alkylcarboxylamino; carboxyl; cyano; halo; or hydroxy;

B, B' and B" each independently represent; C2-C20 alkenoyl; aroyl; or aralkanoyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR'", -O-, or -S-.

62.2. (Currently Amended) A method according to claim 611, wherein R' represents -CO₂R'", CO₂Z' or -CONR₂"".

63-64. (Cancelled).

Application No. 09/843,167 Amendment dated October 14, 2005 Page 4

- A method according to claim 622, wherein X is (Currently Amended) 66. <u>3.</u> -S- and X' is >NH.
- A method according to claim 622, wherein at (Currently Amended) 71. <u>4.</u> least two A groups represent a hydrogen atom.
- A method according to claim 622 wherein R' (Currently Amended) 115. <u>5.</u> represents -CO₂R'".
- A method according to claim 4155, wherein X (Currently Amended) 67. 6. is -S- and X' is >NH.
- A method of claim 676 wherein the bond (Currently Amended) 125. <u>7.</u> labeled "b" in formula I represents a double bond and the bond labeled "a" in formula I represents a single bond.
- A method according to claim 1155 wherein R" (Currently Amended) 116. <u>9.</u> represents methyl.
- (Currently Amended) A method according to claim 1257 wherein A', A", 132. <u>8.</u> B' and B" all represent hydrogen atoms.
- A method according to claim 1169 wherein said (Currently Amended) 73. <u>10.</u> A group represents methoxy.
- A method according to claim 622 wherein R' (Currently Amended) 117. <u>11.</u> represents -CO₂Z'.
- A method according to claim 44711, wherein X (Currently Amended) 68. <u>12.</u> is -S- and X' is >NH.

Application No. 09/843,167 Amendment dated October 14, 2005 Page 5

- A method of claim 6812 wherein the bond (Currently Amended) 126. <u>13.</u> labeled "b" in formula I represents a double bond and the bond labeled "a" in formula I represents a single bond.
- A method according to claim 11711 wherein Z' (Currently Amended) 118. <u>14.</u> is a pharmaceutically acceptable counter ion.
- The method of claim 41814 wherein said (Currently Amended) 74. <u>15.</u> pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.
- A method according to claim 622 wherein R' (Currently Amended) 119. <u>16.</u> represents -CONR2"".
- A method according to claim 11916 wherein at (Currently Amended) 120. <u>17.</u> least one R"" independently represents a hydrogen atom, methyl or methoxy.
- A method according to claim 11916, wherein (Currently Amended) 121. <u>18.</u> both R'" are the same and represent a hydrogen atom, methyl, or methoxy.
- A method according to claim 11916, wherein X (Currently Amended) 122, <u>19.</u> is -S- and X' is >NH.
- A method of claim 11916 wherein the bond (Currently Amended) 127. <u>20.</u> labeled "b" in formula I represents a double bond and the bond labeled "a" in formula I represents a single bond.
- A method of claim 622 wherein at least two A (Currently Amended) 128. <u>21.</u> groups represent methoxy.
- A method of claim 622 wherein said (Currently Amended) 170. <u>22.</u> compound is selected from the group consisting of 3-(3,5-dimethoxyphenyl)-2-{4-[4-(2,4-dloxo-thiazolidin-5-ylmethyl)-phenoxy]phenyl}-acrylic acid,

Application No. <u>09/843,167</u>
Amendment dated October 14, 2005
Page 6

- 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-phenyl}-acrylamide,
- 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-phenyl}-N,N-dimethyl-acrylamide,
- 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-phenyl}-N-methoxy,-N-methyl-acrylamide,
- 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenyl}-propionic acid methyl ester,
- 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenyl}-acrylic acid methyl ester,
- 3-(3,5-dimethoxy-phenyl)-2-(4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-phenyl)-propionic acid,
- 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolid in-5-ylidenemethyl)-phenoxy]-phenyl}-propionic acid,
- 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenyy]-phenyl}-acrylic acid, and
- 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-phenyl}-propionic acid methyl ester.
- 65. 23. (Currently Amended) A method according to claim 611, wherein X is -S- and X' is >NH.
- 69. 24. (Currently Amended) A method according to claim 611, wherein the bond labeled "a" in formula I represents a single bond.
- 124. 25. (Currently Amended) A method according to claim 6924 wherein the bond labeled "b" in formula I represents a double bond.
- 70. 26. (Currently Amended) A method according to claim 611, wherein at least one A group represents methoxy.
- 72. 27. (Currently Amended) A method according to claim 7026, wherein at least two A groups represent a hydrogen atom.

Application No. <u>09/843.16</u>, Amendment dated October 14, 2005 Page 7

75: 28. (Currently Amended) The method of claim 7026 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.


123. 29. (Currently Amended) A method according to claim 611 wherein the bond labeled "b" in formula I represents a double bond.

129. 30. (Currently Amended) A method of claim 611 wherein A' and B' represent hydrogen atoms.

130. 31. (Currently Amended) A method of claim 611 wherein A" and B" represent hydrogen atoms.

131. 32. (Currently Amended) A method of claim 611 wherein A', A", B' and B" all represent hydrogen atoms.

76. 33. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:



in a physiologically acceptable carrier;

wherein Z is

Application No. <u>09/843,167</u>
Amendment dated October 14, 2005
Page 8

n, m, q and r independently represent integers from zero to 4 provided that n+m<4 and q+r<4; p and s independently represent integers from zero to 5 provided that p+s<5; a and b represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R- or S- configuration;

R and R' each independently represent a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z '; - CO_2R '''; - NH_2 ; - NH_2 '''; - NH_2 ''''; - NH_2 '''''; - NH_2 '''''; -

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; -NHR'''; $-NR_2'''$; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R''' independently represents a linear or branched C_1 - C_{20} alkyl; or linear or branched C_2 - C_{20} alkenyl;

R"" independently represents a hydrogen atom; optionally substituted C_1 - C_{20} alkyl; or optionally substituted C_1 - C_{20} alkoxy;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

Application No. <u>09/843,167</u>
Amendment dated October 14, 2005
Page 9

A, and A' each independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkoxy; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylamino; carboxyl; cyano; halo; or hydroxy;

A" independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} acyloxy; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylcarboxylamino; carboxyl; cyano; or halo;

B, B' and B" each independently represent; C2-C20 alkenoyl; aroyl; or aralkanoyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR"', -O-, or -S-.

- 77. 34. (Currently Amended) A method according to claim 7633, wherein R' represents -CO₂R'", -CO₂Z' or -CONR₂"".
- 81. 35. (Currently Amended) A method according to claim 7734, wherein X is -S- and X' is >NH.
- 85. 36. (Currently Amended) A method according to claim 7734, wherein at least one A group represents methoxy.
- 87. 37. (Currently Amended) A method according to claim 8536, wherein at least two A groups represent a hydrogen atom.
- 90. 38. (Currently Amended) The method of claim 8536 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonlum, tromethamine, or tetramethylammonium.
- 86. 39. (Currently Amended) A method according to claim 7734, wherein at least two A groups represent a hydrogen atom.

Application No. <u>09/843,16'r</u>
Amendment dated October 14, 2005
Page 10

- 133. 40. (Currently Amended) A method according to claim 7734 wherein R' represents -CO₂R'''.
- 78. 41. (Currently Amended) A method according to claim 13340 wherein R'" represents methyl.
- 82. 42. (Currently Amended) A method according to claim 43340; wherein X is -S- and X' is >NH.
- 134. 43. (Currently Amended) A method according to claim 13340 wherein R'" represents methyl.
- 88. 44. (Currently Amended) A method according to claim 13443 wherein said A group represents methoxy.
- 142. 45. (Currently Amended) A method of claim 13340 wherein the bond labeled "b" in formula I represents a double bond and the bond labeled "a" in formula I represents a single bond.
- 149. 46. (Currently Amended) A method according to claim 13340 wherein A', A", B' and B" all represent hydrogen atoms.
- 135. 47. (Currently Amended) A method according to claim 7734 wherein R' represents -CO₂Z'.
- 83. 48. (Currently Amended) A method according to claim 13547, wherein X is -S- and X' is >NH.
- 143. 49. (Currently Amended) A method of claim 13547 wherein the bond labeled "b" in formula I represents a double bond and the bond labeled "a" in formula I represents a single bond.
- 436. 50. (Currently Amended) A method according to claim 43547 wherein Z' is a pharmaceutically acceptable counter ion.

Application No. 09/843,16, Amendment dated October 14, 2005 Page 11

- 89. 51. (Currently Amended) The method of claim 13650 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.
- 437. 52. (Currently Amended) A method according to claim 43650 wherein R' represents -CONR₂"".
- 79. 53. (Currently Amended) A method according to claim 13752 wherein both R''' are the same and represent a hydrogen atom, methyl, or methoxy.
- 138. 54. (Currently Amended) A method according to claim 13752 wherein at least one R"" independently represents a hydrogen atom, methyl or methoxy.
- 139. 55. (Currently Amended) A method according to claim 13752, wherein both R''' are the same and represent a hydrogen atom, methyl, or methoxy.
- 144. 56. (Currently Amended) A method of claim 13752 wherein the bond labeled "b" in formula I represents a double bond and the bond labeled "a" in formula I represents a single bond:
- 145. 57. (Currently Amended) A method of claim 7734 wherein at least two A groups represent methoxy.
- 80. 58. (Currently Amended) A method according to claim 7633, wherein X is -S- and X' is >NH.
- 84. 59. (Currently Amended) A method according to claim 7633, wherein the bond labeled "a" in formula I represents a single bond.
- 141. 60. (Currently Amended) A method according to claim 8459 wherein the bond labeled "b" in formula I represents a double bond.

Application No. <u>09/843,167</u>
Amendment dated October 14, 2005
Page 12

440. 61. (Currently Amended) A method according to claim 7633 wherein the bond labeled "b" in formula I represents a double bond.

146. 62. (Currently Amended) A method of claim 7633 wherein A' and B' represent hydrogen atoms.

147. 63. (Currently Amended) A method of claim 7633 wherein A" and B" represent hydrogen atoms.

148. 64. (Currently Amended) A method of claim 7633 wherein A', A", B' and B" all represent hydrogen atoms.

91. 65. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

in a physiologically acceptable carrier;

wherein Z is

or

Application No. 09/843,167
Amendment dated October 14, 2005
Page 13

n, m, q and r independently represent integers from zero to 4 provided that n + m < 4 and q + r < 4; p and s independently represent integers from zero to 5 provided that p + s < 5; a, b and c represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R- or S- configuration;

R independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ''; - NH_2 '''; - NH_2 ''''; - NH_2 ''''; - NH_2 ''''; - NH_2 ''''; - NH_2 ''

R' independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; -NHR'''; $-NR_2'''$; -OR'''; $-CO_2R'''$; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; -NHR'''; - NR_2''' ; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R'" independently represents a linear or branched C_i - C_{20} alkyl; or linear or branched C_2 - C_{20} alkenyl;

R"" independently represents a hydrogen atom; optionally substituted C_1 - C_{20} alkyl; or optionally substituted C_1 - C_{20} alkoxy;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

Application No. <u>09/843,16</u>, Amendment dated October 14, 2005 Page 14

- A, A' and A" each independently represent a hydrogen atom; C₁-C₂₀ acylamino; C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl; C₁-C₂₀ alkoxycarbonyl; C₁-C₂₀ alkoxy; C₁-C₂₀ alkylcarboxylamino; Carboxyl; cyano; halo; or hydroxy;
- B, B' and B" each independently represent; C2-C20 alkenoyl; aroyl; or aralkanoyl;
- or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR'", -O-, or -S-.

- 92. 66. (Currently Amended) A method according to claim 9165, wherein R' represents -CO₂R''', CO₂Z' or -CONR₂''''.
- 96. 67. (Currently Amended) A method according to claim 9266, wherein X is –S- and X' is >NH.
- 99. 68. (Currently Amended) A method according to claim 9266, wherein the bond labeled "a" represents a single bond.
- 159. 69. (Currently Amended) A method according to claim 9968 wherein the bond labeled "b" in formula I represents a double bond.
- 100. 70. (Currently Amended) A method according to claim 92.66, wherein at least one A group represents methoxy.
- 102. 71. (Currently Amended) A method according to claim 10070, wherein at least two A groups represent a hydrogen atom.
- 105. 72. (Currently Amended) The method of claim 10070 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.

- 101. 73. (Currently Amended) A method according to claim 9266, wherein at least two A groups represent a hydrogen atom.
- 150. 74. (Currently Amended) A method according to claim 9266 wherein R' represents -CO₂R".
- 93, 75. (Currently Amended) A method according to claim 15074 wherein R'" represents methyl.
- 97. 76. (Currently Amended) A method according to claim 45074, wherein X is -S- and X' is >NH.
- 151. 77. (Currently Amended) A method according to claim 15074 wherein R" represents methyl.
- 103. 78. (Currently Amended) A method according to claim 15177 wherein said A group represents methoxy.
- 160. 79. (Currently Amended) A method of claim 15074 wherein the bond labeled "b" in formula I represents a double bond and the bond labeled "a" in formula I represents a single bond.
- 452. 80. (Currently Amended) A method according to claim 9266 wherein R' represents -CO₂Z'.
- 98. 81. (Currently Amended) A method according to claim 45280, wherein X is -S- and X' is >NH.
- 153. 82, (Currently Amended) A method according to claim 15280 wherein Z' is a pharmaceutically acceptable counter ion.
- 104. 83. (Currently Amended) The method of claim 15382 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.

Application No. <u>09/843.16</u>, Amendment dated October 14, 2005 Page 16

- 161. 84. (Currently Amended) A method of claim 15280 wherein the bond labeled "b" in formula I represents a double bond and the bond labeled "a" in formula I represents a single bond.
- 154. 85. (Currently Amended) A method according to claim 9266 wherein R' represents -CONR₂".
- 94. 86. (Currently Amended) A method according to claim 45485 wherein both R"" are the same and represent a hydrogen atom, methyl, or methoxy.
- 155. 87. (Currently Amended) A method according to claim 15485 wherein at least one R''' independently represents a hydrogen atom, methyl or methoxy.
- 456. 88. (Currently Amended) A method according to claim 45587 wherein both R"" are the same and represent a hydrogen atom, methyl, or methoxy.
- 157, 89. (Currently Amended) A method according to claim 15485, wherein X is -S- and X' is >NH.
- 162. 90. (Currently Amended) A method of claim 15485 wherein the bond labeled "b" in formula I represents a double bond and the bond labeled "a" in formula I represents a single bond.
- 95. 91. (Currently Amended) A method according to claim 9165, wherein X is -S- and X' is >NH.
- 458. 92. (Currently Amended) A method according to claim 9165 wherein the bond labeled "b" in formula I represents a double bond.
- 106. 93. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

Application No. <u>09/843,16</u>, Amendment dated October 14, 2005 Page 17

$$Z = \begin{bmatrix} A''_n \\ B''_m \end{bmatrix} X'$$

$$\begin{bmatrix} 1 \end{bmatrix}$$

in a physiologically acceptable carrier;

wherein Z is

n, m, q and r independently represent integers from zero to 4 provided that n + m < 4 and q + r < 4; p and s independently represent integers from zero to 5 provided that p + s < 5; a and b represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R- or S- configuration;

R and R' each independently represent a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ; - NH_2 "; -NH

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; -NHR'''; $-NR_2'''$; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

Application No. 09/843,16, Amendment dated October 14, 2005 Page 18

R" independently represents a linear or branched C_1 - C_{20} alkyl; or linear or branched C_2 - C_{20} alkenyl;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, A' and A" each independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkoxy; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylcarboxylamino; carboxyl; cyano; halo; or hydroxy;

B, B' and B" each independently represent; C2-C20 alkenoyl; aroyl; or aralkanoyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR", -O-, or -S-.

107. 94. (Currently Amended) A method according to claim 10693, wherein R' represents -CO₂R'" or CO₂Z'.

109. 95. (Currently Amended) A method according to claim 10794, wherein X is -S- and X' is >NH.

163. 96. (Currently Amended) A method according to claim 10794 wherein R' represents -CO₂R'".

164. 97. (Currently Amended) A method according to claim 16396 wherein R" represents methyl.

167. 98. (Currently Amended) A method according to claim 16396, wherein X is -S- and X' is >NH.

165. 99. (Currently Amended) A method according to claim 10794 wherein R' represents -CO₂Z'.

Application No. <u>09/843,16.</u>
Amendment dated October 14, 2005
Page 19

166. 100. (Currently Amended) A method according to claim 16599 wherein Z' is a pharmaceutically acceptable counter ion.

168. 101. (Currently Amended) A method according to claim 16599, wherein X is -S- and X' is >NH.

108. 102. (Currently Amended) A method according to claim 10693, wherein X is -S- and X' is >NH.

110. 103. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

$$Z = \begin{bmatrix} A^{"n} & & & \\$$

in a physiologically acceptable carrier;

wherein Z is

n, m, q and r independently represent integers from zero to 4 provided that n + m < 4 and q + r < 4; p and s independently represent integers from zero to 5 provided that p + s < 5; a and b represent double bonds which may be present or absent; when DCDB01 20767684.1 14-0ci-05 12:12

Application No. 09/843.16, Amendment dated October 14, 2005 Page 20

present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R- or S- configuration;

R and R' each independently represent a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 "; -N

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; -NHR'''; $-NR_2'''$; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R"' independently represents a linear or branched C_1 - C_{20} alkyl; or linear or branched C_2 - C_{20} alkenyl;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, and A' each independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkoxy; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylamino; carboxyl; cyano; halo; or hydroxy;

A" independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} acyloxy; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylcarboxylamino; carboxyl; cyano; or halo;

B, B' and B" each independently represent; C2-C20 alkenoyl; aroyl; or aralkanoyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR", -O-, or -S-.

111, 104. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a

Application No. 09/843.16; Amendment dated October 14, 2005 Page 21

therapeutically effective amount of a compound represented by the following formula 1:

in a physiologically acceptable carrier;

wherein Z is

n, m, q and r independently represent integers from zero to 4 provided that n + m < 4 and q + r < 4; p and s independently represent integers from zero to 5 provided that p + s < 5; a, b and c represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R- or S- configuration;

R independently represents a hydrogen atom; linear or branched C₁-C₂₀ alkyl; linear or branched C₂-C₂₀ alkenyl; -CO₂Z'; -CO₂R'''; -NH₂; -NHR'''; -NR₂'''; -OH; -OR'''; DCDB01 20767684.1 14-Oct-05 12:12

Application No. <u>09/843,16</u>, Amendment dated October 14, 2005 Page 22

halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R' independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; -NHR'''; $-NR_2'''$; -OR'''; $-CO_2R'''$; $-CO_2R''$; $-CO_2R$

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; -NHR'''; - NR_2''' ; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R" independently represents a linear or branched C_1 - C_{20} alkyl; or linear or branched C_2 - C_{20} alkenyl;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, A' and A" each independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_{1-} - C_{20} alkanoyl; C_{1-} - C_{20} alkoxycarbonyl; C_{1-} - C_{20} alkoxy; C_{1-} - C_{20} alkylamino; C_{1-} - C_{20} alkylcarboxylamino; carboxyl; cyano; halo; or hydroxy;

B, B' and B" each independently represent; C2-C20 alkenoyl; aroyl; or aralkanoyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR", -O-, or -S-.

112. 105. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of 3-(3,5-dimethoxyphenyl)-2-(4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl}-acrylic acid in a physiologically acceptable carrier.

Application No. 09/843,16.

Amendment dated October 14, 2005

Page 23

113. 106. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thlazolidin-5-ylmethyl)-phenoxy]-phenyl}-acrylamide in a physiologically acceptable carrier.

414. 107. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of 5-(4-(4-(1-carbomethoxy-2-(3,5-dimethoxy phenyl)-phenoxy)-benzyl)-2,4-thiazolidinedione in a physiologically acceptable carrier.

169. 108. (Currently Amended) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5ylmethyl)-phenoxy]-phenyl}-N,N-dimethyl-acrylamide, a physiologically acceptable carrier.